<qa>  What is the purpose of this trial?The purpose of this trial is to assess the safety of MyoCellTMexpanded autologous skeletal myoblasts using a dose escalation methodology following epicardial injection into myocardial scar tissue in patients who have experienced anterior, lateral, posterior or inferior wall myocardial infarction, require coronary artery bypass graft CABG surgery and who have an implantable cardioverter defibrillator ICD in place ICD can be implanted during the CABG procedure or 3 to 4 days post CABG procedure. Safety endpoints will be the evaluation of the nature and frequency of Adverse Events during the 12-month period following MyoCellTM treatment. 